{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:41:06Z","timestamp":1791484866242,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["45\/12\/2015\/HAE-BMS"],"award-info":[{"award-number":["45\/12\/2015\/HAE-BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.gene.2018.11.005","type":"journal-article","created":{"date-parts":[[2018,11,3]],"date-time":"2018-11-03T09:40:21Z","timestamp":1541238021000},"page":"85-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia"],"prefix":"10.1016","volume":"686","author":[{"given":"Ramachandran Krishna","family":"Chandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayanan","family":"Geetha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunnathur Murugesan","family":"Sakthivel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandran Geetha","family":"Aswathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preethi","family":"Gopinath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thampirajan Vimaladevi Akhila","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetha","family":"Priya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagathnath Krishna Kumarapillai Mohanan","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hariharan","family":"Sreedharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gene.2018.11.005_bb0005","first-page":"411","article-title":"A complex translocation t (5; 9; 22) in Philadelphia cells involving the short arm of chromosome 5 in a case of chronic myelogenous leukemia","volume":"26","author":"Al-Achkar","year":"2007","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.gene.2018.11.005_bb0010","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1046\/j.1365-2141.2002.03765.x","article-title":"Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase\u2013a report from the Swedish CML Group","volume":"118","author":"Axdorph","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.gene.2018.11.005_bb0015","doi-asserted-by":"crossref","first-page":"6432","DOI":"10.1038\/sj.onc.1208796","article-title":"Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia","volume":"24","author":"Barnes","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.gene.2018.11.005_bb0020","first-page":"247","article-title":"Clonal evolution with isodicentric Ph1 chromosome in Ph1-positive CML: karyotypic conversion after bone marrow transplantation","volume":"48","author":"Becher","year":"1984","journal-title":"Blutalkohol"},{"key":"10.1016\/j.gene.2018.11.005_bb0025","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/gcc.20487","article-title":"Genomic profile of chronic myelogenous leukemia: imbalances associated with disease progression","volume":"46","author":"Brazma","year":"2007","journal-title":"Genes Chromosom. Cancer"},{"key":"10.1016\/j.gene.2018.11.005_bb0030","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.gene.2018.11.005_bb0035","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0165-4608(02)00615-5","article-title":"BCR\/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration","volume":"139","author":"Campbell","year":"2002","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.gene.2018.11.005_bb0040","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cancergencyto.2010.01.012","article-title":"Multiple copies of a rare rearrangement of Philadelphia chromosome in a chronic myeloid leukemia patient: a case report","volume":"199","author":"Chua","year":"2010","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.gene.2018.11.005_bb0045","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.gene.2018.11.005_bb0050","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.gene.2018.11.005_bb0055","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ajh.21457","article-title":"Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia","volume":"84","author":"Foroni","year":"2009","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.gene.2018.11.005_bb0060","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.gene.2018.11.005_bb0065","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/1097-0320(20010201)43:2<101::AID-CYTO1024>3.0.CO;2-8","article-title":"Improvements in cytogenetic slide preparation: controlled chromosome spreading, chemical aging and gradual denaturing","volume":"43","author":"Henegariu","year":"2001","journal-title":"Cytometry A"},{"key":"10.1016\/j.gene.2018.11.005_bb0070","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.hoc.2004.03.001","article-title":"Clinical resistance to imatinib: mechanisms and implications","volume":"18","author":"Hochhaus","year":"2004","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/j.gene.2018.11.005_bb0075","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3109\/10428194.2013.845883","article-title":"Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia","volume":"55","author":"Jabbour","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.gene.2018.11.005_bb0080","series-title":"ASH Education Program Book","first-page":"436","article-title":"Chronic myeloid leukemia stem cells","volume":"2008","author":"Jamieson","year":"2008"},{"key":"10.1016\/j.gene.2018.11.005_bb0085","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.gene.2018.11.005_bb0090","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","article-title":"Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.gene.2018.11.005_bb0095","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.gene.2018.11.005_bb0100","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.gene.2018.11.005_bb0105","first-page":"344A","article-title":"BCR\/ABL gene amplification: a possible mechanism of drug resistance in patients treated with an ABL-specific kinase inhibitor","volume":"96","author":"Mohammed","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.gene.2018.11.005_bb0110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1034\/j.1600-0609.2003.00046.x","article-title":"Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib","volume":"70","author":"Morel","year":"2003","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.gene.2018.11.005_bb0115","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood-2003-02-0371","article-title":"Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate","volume":"103","author":"O'Dwyer","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.gene.2018.11.005_bb0120","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1182\/blood-2008-07-170282","article-title":"The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells","volume":"114","author":"Oehler","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.gene.2018.11.005_bb0125","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.gene.2018.11.005_bb0130","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.gene.2018.11.005_bb0135","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000458164","article-title":"Isodicentric Philadelphia chromosome: a rare chromosomal aberration in imatinib-resistant chronic myelogenous leukemia patients-case report with review of the literature","volume":"150","author":"Ramachandran","year":"2016","journal-title":"Cytogenet. Genome Res."},{"key":"10.1016\/j.gene.2018.11.005_bb0140","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR\u2013ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.gene.2018.11.005_bb0145","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2007-07-102533","article-title":"RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance","volume":"111","author":"Roche-Lestienne","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.gene.2018.11.005_bb0150","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cancergencyto.2006.12.001","article-title":"Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec)-resistant patients","volume":"174","author":"Szych","year":"2007","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.gene.2018.11.005_bb0155","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1182\/blood.V112.11.3190.3190","article-title":"Gene expression profile (GEP) of chronic myeloid leukemia (CML) patients at diagnosis: two distinguished subgroups of CML patients identified, based on a molecular signature, irrespective of their Sokal risk score","volume":"112","author":"Terragna","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.gene.2018.11.005_bb0160","doi-asserted-by":"crossref","first-page":"657","DOI":"10.4314\/tjpr.v16i3.22","article-title":"Quantification of BCR-ABL transcripts in peripheral blood cells and plasma of chronic myeloid leukemia patients at different stages of tyrosine kinase inhibitor treatment response","volume":"16","author":"Ting","year":"2017","journal-title":"Trop. J. Pharm. Res."},{"key":"10.1016\/j.gene.2018.11.005_bb0165","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1600-0609.2011.01689.x","article-title":"Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review","volume":"87","author":"Vaidya","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.gene.2018.11.005_bb0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1755-8166-3-15","article-title":"Genomic amplification of BCR\/ABL1 and a region downstream of ABL1 in chronic myeloid leukaemia: a FISH mapping study of CML patients and cell lines","volume":"3","author":"Virgili","year":"2010","journal-title":"Mol. Cytogenet."},{"key":"10.1016\/j.gene.2018.11.005_bb0175","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.beha.2009.04.002","article-title":"The impact of gene profiling in chronic myeloid leukaemia","volume":"22","author":"Yong","year":"2009","journal-title":"Best Pract. Res. Clin. Haematol."}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111918311430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111918311430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T16:15:54Z","timestamp":1605370554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111918311430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":35,"alternative-id":["S0378111918311430"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2018.11.005","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2018.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}